301520.SZ
万邦医药
SZSE · M 科研服务 · CN
CNY 77.10
+8.36%Year over year
Reported trailing growth
- Revenue
- -35.1%
- EBITDA
- —
- EBIT
- -58.2%
- EPS
- -64.3%
- Free cash flow
- —
- Operating cash flow
- -84.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- -18.5%
- EBIT
- -26.9%
- Net income
- -28.3%
- EPS
- -34.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026